This is in accordance with our results showing a better overall survival in high-grade serous ovarian cancer patients having high OCT1 mRNA levels, which could mediate increasing uptake of both platinum and paclitaxel (Fig. 7)12, 15, 36. The gene discussed is SLC22A1; the disease is ovarian serous adenocarcinoma.